These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37961884)

  • 21. Science and regulatory rituals associated with the drug development process.
    Versteegh LR
    Food Drug Law J; 1997; 52(2):155-61. PubMed ID: 10557552
    [No Abstract]   [Full Text] [Related]  

  • 22. Regulatory science: Researchers in the pipeline.
    Dance A
    Nature; 2013 Apr; 496(7445):387-9. PubMed ID: 23646375
    [No Abstract]   [Full Text] [Related]  

  • 23. Perspectives on an alternative career path in regulatory science.
    Fields FO
    Mol Biol Cell; 2013 Jul; 24(14):2157-9. PubMed ID: 23846346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of the drug approval process between United States and Japan].
    Akera T
    Nihon Yakurigaku Zasshi; 2000 Jul; 116(1):57. PubMed ID: 10976456
    [No Abstract]   [Full Text] [Related]  

  • 25. [Regulatory Science in the Review of Drugs and Medical Devices].
    Koide A
    Yakugaku Zasshi; 2016; 136(4):557-62. PubMed ID: 27040338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States.
    Pieterson EA
    J Clin Pharmacol; 1992 Oct; 32(10):889-96. PubMed ID: 1447395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of Pediatric Drug Approval Lag in Japan.
    Ueyama E; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The European Medicines Agency's goals for regulatory science to 2025.
    Hines PA; Guy RH; Humphreys AJ; Papaluca-Amati M
    Nat Rev Drug Discov; 2019 Jun; 18(6):403-404. PubMed ID: 31160761
    [No Abstract]   [Full Text] [Related]  

  • 29. The Food and Drug Administration gets new tools to spur regulatory science.
    Norman B
    Health Aff (Millwood); 2012 Sep; 31(9):1919-22. PubMed ID: 22949438
    [No Abstract]   [Full Text] [Related]  

  • 30. US drug approval ignores science's subtleties, experts say.
    Waltz E
    Nat Med; 2006 Apr; 12(4):373. PubMed ID: 16598269
    [No Abstract]   [Full Text] [Related]  

  • 31. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
    Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
    Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One hundred years of drug regulation: where do we go from here?
    Woosley RL
    Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.
    Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y
    Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the scientific issues embedded in the generic drug approval process.
    Welage LS; Kirking DM; Ascione FJ; Gaither CA
    J Am Pharm Assoc (Wash); 2001; 41(6):856-67. PubMed ID: 11765111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Express approval of immune checkpoint inhibitors: a conflict between science and finance.
    Kourie HR; Tabchi S; Kattan J
    Future Oncol; 2016 May; 12(10):1215-7. PubMed ID: 26953015
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacology and regulatory science foresee drug development].
    Tsukamoto K
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):4-8. PubMed ID: 27430671
    [No Abstract]   [Full Text] [Related]  

  • 37. Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
    Hirota S; Yamaguchi T
    Clin Pharmacol Ther; 2020 Nov; 108(5):985-994. PubMed ID: 31869436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approving molecularly targeted drugs: different approval processes for cytotoxic agents.
    Sasahara Y; Narimatsu H; Fukao A; Yoshioka T
    Int J Clin Oncol; 2016 Oct; 21(5):1004-1013. PubMed ID: 27105626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The timeliness of new drug approvals in Canada.
    Rawson NS
    Int J Health Serv; 1995; 25(1):153-65; discussion 167-71. PubMed ID: 7794387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
    Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
    Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.